Bulevirtide for treating chronic hepatitis D (TA896)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 June 2023
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 February 2018
Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2018
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 March 2017
Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2017
Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2015
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2015
Sofosbuvir for treating chronic hepatitis C (TA330)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 November 2013Published: 28 January 2004
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 November 2013Published: 23 August 2006
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2010
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2009
Entecavir for the treatment of chronic hepatitis B (TA153)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 August 2008
Telbivudine for the treatment of chronic hepatitis B (TA154)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 August 2008
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2006